Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Wing Yan Josephine Tsang"'
Autor:
Yawen Dong, Tan To Cheung, Ada Law, Ka Wing Ma, Vikki Tang, Tracy Cy Shum, Roland Leung, Gin Wai Kwok, W.H. She, Thomas W.T. Leung, Anna Tai, Jeffrey Sum Lung Wong, Cynthia S Y Yeung, Joanne Wing Yan Chiu, Thomas Yau, Bryan Li, Wing Yan Josephine Tsang
Publikováno v:
Journal of Clinical Oncology. 39:e16179-e16179
e16179 Background: Cabozantinib is licensed for use as second- or third-line treatment for sorafenib-exposed advanced hepatocellular carcinoma (aHCC) based on the phase III CELESTIAL trial. However, its use in the post-immune checkpoint inhibitors (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45d441696a4cb28a6be088075f6f37a9
https://doi.org/10.1200/jco.2021.39.15_suppl.e16179
https://doi.org/10.1200/jco.2021.39.15_suppl.e16179
Autor:
Jess L.C. Chan, Tan To Cheung, Gin Wai Kwok, Jeffrey Sum Lung Wong, Wai Meng David Tai, Joycelyn Jie Xin Lee, Su Pin Choo, Joanne Wing Yan Chiu, Thomas Yau, Bryan Li, Vikki Tang, Roland Leung, Wing Yan Josephine Tsang
Publikováno v:
Journal of Clinical Oncology. 39:e16181-e16181
e16181 Background: Immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) are widely adopted in contemporary advanced HCC (aHCC) treatment algorithms. Nevertheless, the optimal strategy for treatment after ICI exposure is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf4be4e5b35b4d8bb549f32367a5b2c9
https://doi.org/10.1200/jco.2021.39.15_suppl.e16181
https://doi.org/10.1200/jco.2021.39.15_suppl.e16181
Autor:
Wing Yan Josephine Tsang, Gin Wai Kwok, Thomas Yau, Bryan Li, Tan To Cheung, Ka Wing Ma, Jeffrey Sum Lung Wong, W.H. She, Vikki Tang, Roland Leung, Joanne Wing Yan Chiu
Publikováno v:
Journal of Clinical Oncology. 39:e16184-e16184
e16184 Background: Hepatic derangement commonly accompanies advanced HCC (aHCC) and limits the use of systemic therapies. We aimed to evaluate the use of single agent anti-PD-1 nivolumab or pembrolizumab in Child-Pugh (CP) grade B or C patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2cb23ae9f656d733b8ae24d35118edbe
https://doi.org/10.1200/jco.2021.39.15_suppl.e16184
https://doi.org/10.1200/jco.2021.39.15_suppl.e16184
Autor:
Jeffrey Sum Lung Wong, Wing Yan Josephine Tsang, Gin Wai Kwok, Ka Wing Ma, Roland Leung, Tan To Cheung, Joanne Wing Yan Chiu, W.H. She, Vikki Tang, Thomas Yau, Bryan Li
Publikováno v:
Journal of Clinical Oncology. 39:330-330
330 Background: Programmed cell death protein 1 (PD-1) pathway blockade with immune checkpoint inhibitors (ICI) is a standard therapy in advanced hepatocellular carcinoma (HCC) nowadays. No strategies to overcome ICI resistance have been described. W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cd363cdb8b591362ebea83803387da0
https://doi.org/10.1200/jco.2021.39.3_suppl.330
https://doi.org/10.1200/jco.2021.39.3_suppl.330
Autor:
Thomas Yau, Joanne Wing Yan Chiu, Bryan Li, Yawen Dong, Thomas W.T. Leung, Gin Wai Kwok, Roland Leung, Ka Wing Ma, Wong Hoi She, Jeffrey Sum Lung Wong, Vikki Tang, Wing Yan Josephine Tsang, Tan To Cheung
Publikováno v:
Journal of Clinical Oncology. 39:316-316
316 Background: In the phase III CELESTIAL trial, cabozantinib showed significant improvement in overall survival with good tolerability in advanced HCC population. We aimed to evaluate the efficacy, survival and tolerability of cabozatinib in advanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abee8f960111b9d1d10511c32945935e
https://doi.org/10.1200/jco.2021.39.3_suppl.316
https://doi.org/10.1200/jco.2021.39.3_suppl.316